Do I need an in-person exam for Wegovy in Texas?

If you’re exploring weight loss options, you’ve likely heard about medications like Wegovy, Ozempic, and Mounjaro. These GLP-1 receptor agonists have transformed obesity treatment—but one question keeps coming up: Can you legally get these medications through telehealth?

The short answer is yes—with some important caveats depending on where you live.

This comprehensive guide breaks down federal and state telehealth regulations, explains how GLP-1 prescribing works online, and helps you understand what to expect when seeking weight loss treatment through platforms like Klarity Health.

Understanding Federal Telehealth Rules for Weight Loss Medications

The Good News: GLP-1s Aren’t Controlled Substances

Unlike stimulant-based weight loss medications or ADHD treatments like Adderall, GLP-1 medications (semaglutide, tirzepatide) are not controlled substances. This is a crucial distinction.

Federal law—specifically the Ryan Haight Act—requires an in-person medical examination before prescribing controlled medications via telehealth. However, this rule does not apply to non-controlled drugs like Wegovy, Ozempic, or Mounjaro.

What this means for you: Under federal law, there’s no blanket requirement for an in-person visit before a licensed provider can prescribe GLP-1 weight loss medications through telehealth.

Current Status of Telehealth Flexibilities

During the COVID-19 pandemic, the DEA temporarily waived in-person requirements for all telehealth prescribing, including controlled substances. As of December 2025, these flexibilities have been extended through December 31, 2025, giving regulators more time to develop permanent rules.

While this mainly affects controlled medications, it reflects a broader federal commitment to accessible telehealth care—including obesity treatment.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Telehealth Requirements: What You Need to Know

While federal law permits telehealth prescribing of GLP-1s, individual states can impose additional requirements. Some states require initial in-person exams, mandate specific follow-up schedules, or have unique documentation rules.

Here’s what matters most in the states where Klarity Health operates:

States Requiring an Initial In-Person Exam

Arkansas, Delaware, Georgia, Mississippi, New Jersey, North Dakota, South Carolina, and Texas generally require or strongly recommend an initial in-person physical examination before starting weight loss medication therapy via telehealth.

What this looks like in practice:

• You’ll typically need to visit a local healthcare provider for your first appointment
• This visit includes a physical exam, baseline lab work, and medical history review
• After the initial evaluation, follow-up visits and prescription refills can often be managed through telehealth

Example: In Georgia, state medical board guidance requires an in-person exam to establish the patient-provider relationship before prescribing weight loss medications. However, once established, ongoing management—including dose adjustments and refills—can occur via video consultations.

States Allowing Fully Remote Treatment

California, Connecticut, Illinois, New York, Pennsylvania, Utah, Virginia, and Washington permit telehealth providers to prescribe GLP-1 medications without requiring an in-person visit, provided the provider conducts a thorough virtual evaluation.

What to expect:

• Comprehensive medical history questionnaire
• Live video consultation with a licensed provider
• Discussion of your weight loss goals, previous attempts, and medical conditions
• Review of contraindications and potential side effects
• Development of a treatment plan that includes lifestyle modifications

Important note: Even in states that don’t legally require an in-person exam, your provider may recommend one if your medical situation warrants it. This is good medicine, not red tape.

Special State Requirements to Know

Florida requires:

• BMI ≥30 (or ≥27 with weight-related health conditions)
• Follow-up visits at least every 3 months during treatment

Virginia mandates:

• Initial physical examination and laboratory testing
• A personalized diet and exercise plan
• Follow-up within 30 days of starting medication

Connecticut requires:

• Behavioral counseling component
• Documentation of diet and exercise recommendations

New Jersey has particularly strict standards:

• Comprehensive initial evaluation including psychological screening
• Laboratory work to rule out contraindications
• Detailed informed consent covering all risks

These requirements aren’t meant to create barriers—they’re designed to ensure you receive safe, evidence-based care that maximizes your chances of success.

Who Can Prescribe GLP-1 Weight Loss Medications?

Medical Doctors and Doctors of Osteopathy

MDs and DOs can prescribe GLP-1 medications via telehealth in all states, provided they hold an active medical license in the state where you’re physically located during the consultation.

Nurse Practitioners and Physician Assistants

Nurse Practitioners (NPs) and Physician Assistants (PAs) can also prescribe these medications, but their level of independence varies by state:

Full Independent Practice (34+ states including DC):California, New York, Washington, Arizona, Connecticut, Utah, and others allow NPs to evaluate patients and prescribe medications without physician oversight after meeting experience requirements.

Collaborative Practice:Texas, Florida, Pennsylvania, Georgia (for most medications), and several other states require NPs and PAs to have a supervisory or collaborative agreement with a physician.

What this means for your care: At Klarity Health, you might see an NP, PA, or MD/DO depending on availability and your state’s requirements. All providers are fully licensed and credentialed to practice in your state and provide the same quality of care.

Are You Eligible for GLP-1 Weight Loss Medications?

Legitimate telehealth providers follow evidence-based clinical criteria. You’ll generally need to meet these requirements:

Clinical Eligibility Criteria

Body Mass Index (BMI):

• BMI ≥30 (obesity), or
• BMI ≥27 with at least one weight-related health condition (type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea)

Previous Weight Loss Attempts:Most providers want to see that you’ve tried lifestyle modifications (dietary changes, increased physical activity) before prescribing medication—unless you have medical reasons that make such attempts inadvisable.

Commitment to Lifestyle Changes:GLP-1 medications work best alongside healthy eating and regular exercise. Expect your provider to discuss behavioral changes as part of your treatment plan.

Medical Contraindications

You will NOT qualify for GLP-1 therapy if you have:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Current pregnancy or planning to become pregnant (must discontinue 2+ months before conception)
• History of severe pancreatitis
• Active gallbladder disease
• Severe gastroparesis or other serious GI disorders
• History of suicidal ideation (requires careful evaluation)

Your telehealth provider will screen for these conditions through a detailed medical history questionnaire and consultation.

How Telehealth Weight Loss Treatment Works: A Step-by-Step Guide

1. Initial Consultation

What happens:

• Complete a comprehensive health questionnaire covering your medical history, current medications, allergies, and weight loss goals
• Submit current height and weight (some providers may require photo verification)
• Schedule a live video appointment with a licensed provider

Duration: Typically 20-30 minutes for the initial consultation

2. Medical Evaluation

Your provider will:

• Review your health history and current medications
• Discuss previous weight loss attempts
• Calculate your BMI and assess clinical appropriateness
• Screen for contraindications
• Explain how GLP-1 medications work, including benefits and potential side effects
• Discuss realistic expectations (gradual weight loss over several months, not overnight results)
• Develop a comprehensive treatment plan including dietary and exercise recommendations

Key point: If your provider determines medication isn’t right for you, they’ll explain why and suggest alternative approaches. Responsible telehealth platforms won’t prescribe just because you want a prescription—they prescribe when it’s medically appropriate.

3. Prescription and Medication Delivery

If approved:

• Your provider sends an electronic prescription to your preferred pharmacy (or a partner pharmacy)
• Medications are typically dispensed with detailed injection instructions
• Many telehealth services coordinate home delivery of medications
• You’ll receive training materials on proper injection technique and medication storage

First prescription: Usually 4 weeks of medication to assess tolerance and response

4. Ongoing Monitoring and Follow-Up

Regular check-ins include:

• Weight tracking and progress assessment
• Side effect monitoring (nausea, GI symptoms are common initially)
• Dose adjustments as needed (GLP-1s are typically titrated up gradually)
• Reinforcement of lifestyle modifications
• Lab work if indicated (especially if you have diabetes or other conditions)

Follow-up frequency:

• First month: 2-4 weeks after starting
• Ongoing: Every 1-3 months depending on your state’s requirements and your individual needs

Some states mandate specific follow-up intervals—for example, Florida requires at least one visit every 3 months, and Virginia requires a 30-day follow-up after initiation.

Klarity Health: Transparent, Evidence-Based Weight Loss Care

At Klarity Health, we’ve designed our weight loss program to prioritize your safety while maximizing convenience:

What sets us apart:

✓ Licensed providers in your state: All consultations are conducted by providers licensed where you live, ensuring full compliance with local regulations

✓ Transparent pricing: We accept both insurance and cash pay, with upfront pricing so there are no surprises

✓ Flexible appointment availability: Access providers who understand your schedule, with evening and weekend options available

✓ Comprehensive care approach: We don’t just prescribe medication—we support your entire weight loss journey with lifestyle coaching and ongoing monitoring

✓ Compliance with state-specific requirements: Whether you’re in a state requiring an initial in-person exam or one that allows fully remote care, we’ll guide you through the process and ensure you receive appropriate evaluation

Our providers understand that weight loss is deeply personal. They take time to listen, answer your questions, and develop a treatment plan tailored to your unique situation.

Understanding the Medications: Wegovy, Ozempic, and Mounjaro

Wegovy (Semaglutide 2.4mg)

FDA Status: Approved specifically for chronic weight management

How it works: Weekly injection that mimics GLP-1, a hormone that regulates appetite and blood sugar

Typical results: 12-15% body weight loss over 68 weeks in clinical trials when combined with lifestyle changes

Common side effects: Nausea, diarrhea, constipation, abdominal pain (usually mild and improve over time)

Prescribing considerations: FDA-approved for adults with obesity or overweight with comorbidities. Requires lifestyle intervention alongside medication.

Ozempic (Semaglutide 0.5-1mg)

FDA Status: Approved for type 2 diabetes; commonly used off-label for weight loss

How it differs from Wegovy: Lower dose, same active ingredient

Why providers prescribe it for weight loss: Substantial weight loss observed in diabetes trials; may be more readily available or affordable than Wegovy

Important: When prescribed off-label for weight loss, providers must document medical rationale and obtain informed consent

Mounjaro (Tirzepatide)

FDA Status: Approved for type 2 diabetes (marketed as Mounjaro); obesity-specific formulation approved as Zepbound in late 2023

How it works: Dual-action medication that activates both GLP-1 and GIP receptors

Typical results: Some studies show greater weight loss than semaglutide—up to 20%+ body weight reduction

Current access: Prescribed on-label for diabetes or under the Zepbound brand for obesity; some off-label use of Mounjaro for weight loss continues

Compounded Versions: What You Need to Know

Important FDA update (May 2025): The FDA has banned routine compounding of semaglutide for weight loss, declaring the shortage over. This means:

✗ Compounded ‘Wegovy’ or ‘Ozempic’ from online pharmacies is no longer permitted except in very limited circumstances

✓ FDA-approved brand-name medications are the only legal option for most patients

✓ Reputable telehealth providers have stopped offering compounded versions and now prescribe only FDA-approved products

Why this matters: Compounded medications may have quality control issues, incorrect dosing, or contamination risks. The FDA’s action protects patient safety.

Be cautious of: Any telehealth service still advertising ‘affordable compounded semaglutide’—this may be operating outside current regulations.

Red Flags: How to Spot Unsafe Telehealth Weight Loss Services

The popularity of GLP-1 medications has unfortunately attracted some questionable operators. Here’s what to watch out for:

🚩 Guaranteed Prescriptions

Red flag: ‘Get Ozempic guaranteed!’ or ‘100% approval rate’

Why it’s concerning: Legitimate providers evaluate each patient individually. Not everyone qualifies medically. Services that promise prescriptions without proper evaluation prioritize profit over patient safety.

🚩 No Live Provider Consultation

Red flag: ‘Just fill out a questionnaire—no video call needed’

Why it’s concerning: Most states require a real-time audio-visual consultation to establish a valid patient-provider relationship. Prescription-only based on a form may violate state telehealth laws.

🚩 Compounded or ‘Generic’ Versions

Red flag: Advertising compounded semaglutide or ‘affordable generics’ from overseas

Why it’s concerning: As of 2025, compounding is banned for these medications, and there are no FDA-approved generic versions available in the U.S. These products may be counterfeit, contaminated, or incorrectly dosed.

🚩 No Follow-Up Care

Red flag: One-time prescription with no scheduled monitoring

Why it’s concerning: GLP-1 therapy requires ongoing monitoring for side effects, dose adjustments, and safety. Providers who prescribe and disappear aren’t providing standard-of-care treatment.

🚩 Unclear Provider Credentials

Red flag: No information about who will prescribe, what state they’re licensed in, or their qualifications

Why it’s concerning: Legitimate telehealth platforms are transparent about provider credentials. You have a right to know who’s prescribing your medication and verify their license.

🚩 Skipping Informed Consent

Red flag: No discussion of risks, side effects, or alternatives

Why it’s concerning: Ethical medical practice requires informed consent. You should understand potential complications (including the thyroid cancer warning), common side effects, and what to do if problems arise.

Stick with established telehealth platforms like Klarity Health that prioritize clinical appropriateness, transparent communication, and comprehensive care over quick sales.

Insurance Coverage and Costs

Insurance Coverage

GLP-1 weight loss medications have varying insurance coverage:

Medicare: Generally does not cover weight loss medications (though this may change with pending legislation)

Private insurance: Coverage varies widely

• Some plans cover Wegovy or Zepbound with prior authorization
• Many plans cover Ozempic/Mounjaro for diabetes but not for weight loss alone
• High-deductible plans may require significant out-of-pocket costs even if ‘covered’

Medicaid: Coverage varies by state; some states cover obesity medications, others don’t

Cash Pay Options

If insurance doesn’t cover your medication or the out-of-pocket cost is prohibitive:

Manufacturer savings programs: Novo Nordisk and Eli Lilly offer patient assistance for eligible individuals

Telehealth platforms with negotiated pricing: Some services (including Klarity Health) work with pharmacies to offer competitive cash pricing

Alternative dosing: Your provider might prescribe a lower-cost option (like Ozempic off-label instead of Wegovy) if clinically appropriate

Typical cash costs (without insurance):

• Wegovy: $1,000-$1,400/month
• Ozempic: $900-$1,000/month
• Mounjaro/Zepbound: $1,000-$1,200/month

These are retail prices and may be reduced through savings programs or pharmacy negotiations.

Klarity Health’s Transparent Approach

We accept both insurance and cash pay, and we’re upfront about costs before you commit to treatment. During your consultation, your provider will discuss:

• Whether your insurance is likely to cover the medication
• Cash pay options if insurance denies coverage
• Alternative medications that might be more affordable
• The realistic total cost of treatment (including follow-up visits)

No surprises, no hidden fees—just honest information so you can make an informed decision.

The Future of Telehealth Weight Loss Treatment

Telehealth for obesity care is here to stay, but the regulatory landscape continues to evolve:

What’s on the Horizon

Potential permanent telehealth rules: The DEA is expected to issue new regulations in 2026 that could make pandemic-era telehealth flexibilities permanent for controlled substances (which would signal broader federal support for telemedicine)

State practice authority expansions: Several states (including Mississippi and Pennsylvania) are considering bills to grant nurse practitioners full independent practice, which could expand provider availability for telehealth weight loss care

The TREATS Act: Federal legislation reintroduced in late 2025 that would permanently allow certain telehealth prescribing for substance use disorder treatment—a signal that Congress supports modernizing telehealth access

New obesity medications: Additional GLP-1 and dual-action drugs are in development, which will likely increase telehealth prescribing opportunities

Insurance coverage changes: Advocacy efforts continue to expand Medicare and private insurance coverage for obesity medications, which could make telehealth treatment more affordable

What This Means for You

If you’re considering telehealth weight loss treatment now or in the future:

✓ Access will likely improve as more states modernize regulations and provider networks expand

✓ Quality standards will strengthen as regulators and professional organizations establish clearer telehealth guidelines

✓ Costs may become more manageable if insurance coverage expands and generic versions eventually reach the market

✓ Your state’s requirements may change—stay informed if you’re in a state with restrictive rules, as advocacy efforts are ongoing

Common Questions About Telehealth GLP-1 Prescribing

Q: Do I need to live in a specific state to use telehealth for weight loss medications?

A: You can access telehealth weight loss care in most states, but your provider must be licensed in the state where you’re physically located during the consultation. Platforms like Klarity Health have providers licensed across multiple states to serve patients nationwide.

Q: Can I use telehealth if I’ve never met my provider in person?

A: Yes, in most states. Federal law doesn’t require an in-person meeting for non-controlled medications like GLP-1s. However, some states (Arkansas, Georgia, New Jersey, and several others) do require an initial in-person exam. Your telehealth provider will guide you through your state’s specific requirements.

Q: How long does it take to get a prescription after my first appointment?

A: If you’re approved, your prescription is typically sent to the pharmacy the same day or within 24 hours. Medication delivery depends on your pharmacy’s process—usually 2-7 days.

Q: What if I move to a different state while I’m on treatment?

A: You’ll need to establish care with a provider licensed in your new state. Many telehealth platforms can facilitate this transition by connecting you with an in-network provider in your new location. Your medical records and treatment history will transfer to ensure continuity of care.

Q: Are telehealth consultations as good as in-person visits for weight loss treatment?

A: Research shows that telehealth weight loss programs can be just as effective as in-person care when providers follow evidence-based protocols. The key is thorough initial evaluation, regular monitoring, and a comprehensive approach that includes lifestyle counseling—all of which can be delivered virtually.

Q: What happens if I have side effects?

A: Your telehealth provider should offer accessible support for managing side effects. Most platforms provide messaging portals or phone support. Mild GI side effects (nausea, diarrhea) are common initially and usually improve—your provider can offer strategies to minimize discomfort. Serious side effects warrant immediate medical attention, and your provider will give you clear guidance on warning signs.

Taking the Next Step in Your Weight Loss Journey

If you’re struggling with obesity or weight-related health conditions, GLP-1 medications prescribed through telehealth could be a game-changer—but only when combined with sustainable lifestyle changes and ongoing medical support.

What to do next:

1. Check your eligibility: Calculate your BMI and review the medical criteria outlined above

2. Research your state’s requirements: Use our state-by-state guide to understand what to expect in your location

3. Choose a reputable telehealth provider: Look for platforms with licensed providers, transparent pricing, and comprehensive care models

4. Prepare for your consultation: Gather your medical history, current medications, previous weight loss attempts, and questions you want to ask

5. Set realistic expectations: Understand that medication is a tool, not a magic bullet—success requires commitment to long-term lifestyle changes

Start Your Journey with Klarity Health

At Klarity Health, we make evidence-based weight loss care accessible, affordable, and personalized to your needs. Our licensed providers are ready to:

• Evaluate your medical history and determine if GLP-1 therapy is right for you
• Navigate your state’s specific telehealth requirements
• Develop a comprehensive treatment plan tailored to your goals
• Support you throughout your weight loss journey with regular monitoring and adjustments

Get started today:

• Transparent pricing with both insurance and cash pay options
• Providers available with flexible scheduling, including evenings and weekends
• Comprehensive care that goes beyond prescriptions—we’re partners in your health

Weight loss is challenging, but you don’t have to do it alone. With the right medical support and proven medications delivered through convenient telehealth, you can achieve lasting results.

Ready to take the first step? Connect with a Klarity Health provider today and discover if telehealth weight loss treatment is right for you.

Research Currency Statement

Verified as of: December 17, 2025

DEA Rules Status: DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025. Non-controlled medications (like GLP-1 agonists) are not subject to the Ryan Haight Act’s in-person rule, so they can be prescribed via telehealth under federal law.

States Verified: AR, CA, CT, DE, FL, GA, IL, MS, NJ, NY, ND, PA, SC, TX, UT, VA, WA (as of December 2025)

⚠️ Note: Federal telehealth rules for controlled substances are temporary (set to expire 12/31/2025)—an additional extension or new rule is expected. State laws are constantly evolving. FDA oversight on compounded GLP-1 medications tightened in 2025.

Citations and Sources

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – U.S. Drug Enforcement Administration, November 15, 2024. www.dea.gov

2. COVID-era telehealth prescribing extended – Axios News, November 18, 2024. www.axios.com

3. DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – McDermott Will & Emery Legal Insight, November 18, 2024. www.mwe.com

4. The Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Goodwin Procter Client Alert, March 27, 2024. www.goodwinlaw.com

5. Hims cuts 4% of workforce amid ban on weight-loss drug copies – Reuters, May 30, 2025. www.reuters.com

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid